The venture's AI-driven drug resistance prediction aligns with EIC's deep tech focus. Non-dilutive funding up to €2.5M matches the applicant's target, and the founder's EU location (Île-de-France) is eligible. However, the venture is not yet incorporated, which may be a prerequisite for EIC Accelerator.